JAK inhibitors and the risk of malignancy: a meta-analysis across disease indications

• Results Overview

  When comparing different medications, JAK inhibitors were found to have a higher risk of cancer than TNF inhibitors, but showed no difference in cancer risk compared to placebo or methotrexate. Overall, cancer was a rare occurrence across all treatments.

• Study Summary

  Num Participants:

  None

  Study Type:

  Review

  Control Group:

  ['Placebo', 'Tnf-Α Inhibitors', 'Methotrexate']

  Efficacy End Points Treatment:

  {'Malignancy incidence rate': 1.15}

  Efficacy End Points Control:

  None

  Side Effects Treatment:

  Adverse Event	Severity	Percentage Affected

  Side Effects Control:

  Adverse Event	Severity	Percentage Affected